Navigation Links
3-D kidney atlas created for researchers and physicians
Date:5/15/2009

Renal diseases shall be diagnosed earlier and treated more successfully in the future. Towards this aim, researchers from nine European countries*, coordinated by the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have been working for the past four-and-a half years to create a three-dimensional virtual "Kidney Atlas". It incorporates the latest research findings on the development and diseases of the kidney. The Kidney Atlas was part of the European Renal Genome Project (EuReGene), which the European Union (EU) funded with more than 10 million euros. At the conclusion of the project, the Kidney Atlas was presented at MDC during a two-day symposium from May 15-16, 2009, which was attended by approximately 100 researchers.

In Europe, about 4.5 million people suffer from renal disease. The elderly are disproportionately affected, as the disease frequently develops as a consequence of hypertension and diabetes. However, renal disease is a condition that also affects children, who are often born with congenital renal anomalies.

In particular, the increase in the incidence of type 2 diabetes has caused a rise in the number of renal patients. Loss of kidney function is among the most common causes of death in the Western world. About 20 percent of affected patients die from the disease each year.

Information for the general public

While the primary aim of the Kidney Atlas is to map genes that play a key role in renal diseases, it also contains other data, for example on anatomy. Directed towards both basic researchers and clinicians, the Kidney Atlas also contains information for the general public.

The Atlas is based upon various Genome Projects. The scientists involved in creating the Atlas were pathologists, developmental and molecular biologists as well as geneticists from 14 research groups from non-university institutions, universities and six university clinics.

Accordi
'/>"/>

Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Helmholtz Association of German Research Centres
Source:Eurekalert

Page: 1 2

Related biology news :

1. Diet support helps chronic kidney patients
2. Genetic breakthrough offers promise in tackling kidney tumors
3. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
4. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
5. Gaining a better understanding of kidney diseases
6. High blood pressure takes big toll on small filtering units of the kidney
7. Scientists identify cell changes leading to impaired artificial kidney function
8. Kidney function discovery sheds light on genetic complexity of disease
9. UC San Diego researchers use metagene portraits to reveal distinct stages of kidney formation
10. UC Davis discovery offers hope for treating kidney cancer
11. Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 2005, President George W. Bush and American corn farmers saw ... reduce both American dependence on foreign oil and greenhouse gas ... gallons of renewable fuel be added to the gasoline supply ... and 7.5 billion in 2012. Since then, life cycle ...
... Using the meticulous phenological records of two iconic American naturalists, ... native plants in the eastern United States are flowering as ... climate. The new study is important because it gives ... in response to a warming world. In addition, the work ...
... 16, 2013 EcoHealth Alliance, a nonprofit organization that focuses ... on Ebola virus in fruit bats in the peer reviewed ... the Centers for Disease Control and Prevention (CDC). The ... 276 bats scientists screened in Bangladesh. These results suggest ...
Cached Biology News:Photovoltaics beat biofuels at converting sun's energy to miles driven 2Photovoltaics beat biofuels at converting sun's energy to miles driven 3In the Eastern US, spring flowers keep pace with warming climate 2In the Eastern US, spring flowers keep pace with warming climate 3Recent study suggests bats are reservoir for ebola virus in Bangladesh 2
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Technologies, Inc. , a developer and provider of medical ... second quarter results Tuesday morning, showing both growth and ... high of $18.8 million, the company took a loss ... owing largely to merger and transition costs after acquiring ...
... Madison, Wis. - Esker Software , a provider ... opening of a new mail house at its U.S. headquarters ... Esker on Demand service. , ,The new mail ... facility in Lyon, France and its strategic partners in the ...
... has been appointed to the board of directors of ... former president of the American Society of Therapeutic Radiation ... radiation oncology. , ,Perez is professor emeritus in ... Radiology, Siteman Cancer Center, Washington University Medical Center. , ...
Cached Biology Technology:Cedara acquisition costs hit Merge Technologies numbers 2
...
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
Biology Products: